BioSpace20h
Supernus Taps Potential $300M US Opportunity With FDA Win for Parkinson’s Drug-Device Combo
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...
The Pharma Letter11h
FDA nod at last for Supernus’ Parkinson’s infusion therapy
It’s fourth time lucky for Supernus Pharmaceuticals (Nasdaq: SUPN), as the Parkinson’s specialist finally receives US ...
PMLiVE21h
FDA approves Supernus’ Onapgo to treat advanced Parkinson’s disease
The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection ...
Supernus Pharmaceuticals exec sells shares worth $376,236
Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a company that InvestingPro data shows maintains ...
California Healthline18h
California Healthline Daily Edition
The results were presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium held in San Francisco late last month. They were also published in the Journal of ...